The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells

Andrew M Platt, Robert A Benson, Ross McQueenie, John P Butcher, Martin Braddock, James M Brewer, Iain B McInnes, Paul Garside

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells'. Together they form a unique fingerprint.

Medicine & Life Sciences